Management of Patients with Differentiated Thyroid Carcinoma- SNMB Guidelines

Sultana, Sadia; Nahar, Nurun; Alam, Faridul; Hasan, Mizanul; Hussain, Raihan; Haque, Mahmubul; Nasreen, Faria; Khan, Mohafizul Haque; Nisa, Lutfun; Moslem, Fauzia; Afroz, Shireen; Quadir, Kamila Afroj; Begum, Fatima; Ma, Ketao

doi:10.3329/bjnm.v18i1.34943

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three of the patients presented here were treated with neck dissection followed by RAIT in high doses. NINMAS follows the SNMB protocol as the recommended guideline and usually 200 mCi 131 I is administered in cases of bone metastases from DTC (16) Three patients in this series received RAIT; two of them were initially diagnosed with bone metastasis and received a single dose (150 mCi and 200 mCi, respectively).One was diagnosed with bone metastasis later in therapy and had five doses of RAIT (a total of 750 mCi). One patient was unfit for RAIT, so she got none.…”

Section: Discussion and Literature Reviewmentioning

confidence: 99%

Follicular Thyroid Carcinoma Metastasis to the Skull and Brain: Case Series with Literature Review

Bailey¹,

Ali²,

Ferdous³

et al. 2023

Bangladesh J. Nuclear Med.

View full text Add to dashboard Cite

Distant metastasis is more common in follicular thyroid carcinomas (FTC) than papillary thyroid carcinomas (PTC), as vascular invasion is often characteristic of FTC. Lung, bone, brain, liver, bladder, and skin are potential sites of distant metastases. On the other hand, lymph node involvement is much less common (8–10%) in cases of FTC compared to PTC. The therapy of patients may be significantly impacted by learning more about the epidemiological features of thyroid metastases at uncommon sites. In our experience, metastases in uncommon sites do not always indicate a poor prognosis for differentiated thyroid carcinoma (DTC), which might be due to the disease patterns. Every year, around 5% new FTC patients are registered, treated with radioiodine, and followed up in the thyroid division of National Institute of Nuclear Medicine and Allied Sciences (NINMAS). Four FTC patients (F=3, M=1) with skull bone and brain metastases are discussed in this case series. All of them were post thyroidectomized and were referred to NINMAS for radioiodine ablation therapy (RAIT). Two of them had skull and brain metastases, third patient had extensive skull, facial bone and pubic bone invasion, whereas, fourth patient had multiple skull metastases. Bangladesh J. Nuclear Med. 25(2): 128-137, 2022

show abstract

Section: Discussion and Literature Reviewmentioning

confidence: 99%

Follicular Thyroid Carcinoma Metastasis to the Skull and Brain: Case Series with Literature Review

Bailey¹,

Ali²,

Ferdous³

et al. 2023

Bangladesh J. Nuclear Med.

View full text Add to dashboard Cite

show abstract

“…Preoperative estimation of the level of risk for diseasespecific recurrence in WDTC is essential to determine whether to perform HT or TT. The incidence and clinical implications of high-risk features discovered postoperatively in patients with preoperatively determined low-risk WDTC are yet to be better defined (9)(10)(11).…”

Section: Discussionmentioning

confidence: 99%

“…Patients who had been classified as low-risk before surgery were escalated in risk stratification and re-classified after surgery as intermediate-to-high risk if gross extrathyroidal extension had been observed intraoperatively with concordant microscopic extra-thyroidal extension in final histopathology, if the final histopathology results showed aggressive histology (e.g., tall cell, diffuse sclerosing variant), perineural (7)(8)(9) or lymphovascular invasion, if there were more than 5 positive involved lymph nodes (larger than 0.2 cm) within the specimen, or if extra-nodal extension, incomplete tumor resection (positive margins) or distant metastases had been detected during or after surgery (5).…”

Section: Risk Stratificationmentioning

confidence: 99%

The incidence of postoperative re-stratification for recurrence in well-differentiated thyroid cancer—a retrospective cohort study

Neiderman¹,

Duek²,

Ravia³

et al. 2021

Gland Surg

View full text Add to dashboard Cite

Background: After diagnosing well-differentiated thyroid cancer (WDTC), assessment of the risk for disease-specific recurrence is essential for deciding between hemi-thyroidectomy (HT) and total thyroidectomy (TT). The American Thyroid Association (ATA) 2015 guidelines suggest that patients with 1-4 cm WDTC without suspicious features may be suitable for HT. Patients' preoperatively determined risk levels are re-stratified according to surgical and final histopathological findings. The incidence and clinical implications of high-risk features discovered postoperatively in patients with preoperatively determined lowrisk WDTC are yet to be better defined.

show abstract

“…Therapeutic NM in Bangladesh began in the early 1980s with the application of radioactive iodine ( 131 I) in thyroid cancer and primary hyperthyroidism. The first radioactive iodine therapy (RAIT) for thyroid cancer was given at NINMAS in 1980 (NINMAS records), and it soon became a routine procedure in the management of differentiated thyroid cancer (DTC) and primary hyperthyroidism both at NINMAS and other NM centers in the country [5,6].…”

mentioning

confidence: 99%

“…Since then, a large number of patients were treated following the protocol, and huge information and experiences were obtained resulting a need to further upgrade the protocol. In 2014, the national guideline for RAIT of DTC and primary hyperthyroidism was proposed through a national conference of SNMB, which was approved, and after approval in 2015, the national guidelines were published in BJNM [6,9].…”

mentioning

confidence: 99%

Theranostics in Bangladesh: Current Status, Challenges, and Future Perspective

Begum

Nisa

Sarker

2019

Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Background and Current Status of Theranostics Therapeutic nuclear medicine (NM) in Bangladesh began in the early 1980s with the application of radioactive iodine for treatment of thyroid cancer and primary hyperthyroidism. Since then, NM practice has remarkably developed in the country with the advancement of instrumentation, radiopharmacy, and information technology. The government took the initiative to establish four PET-CT centers at different NM centers, including one at the National Institute of Nuclear Medicine and Allied Sciences (NINMAS). A further development is the installation of a cyclotron center (18-MeV cyclotron) at NINMAS by the government's fund. Currently, NM is providing good health services to oncology patients throughout the country. More than 20 NM centers are functioning in different parts of the country, and therapeutic NM has an important place. However, conventional radioactive iodine still remains the major theranostic application. Challenges and Future Perspective The expansion and development of therapeutic NM for other cancers have been limited due to a number of challenging factors. A brief overview of the history and current status of NM in Bangladesh is presented here with an examination of factors that pose as obstacles to the introduction and development of new therapeutic technologies. Finally, future perspectives are discussed with ways to mitigate existing problems and challenges. Keywords Theranostics . Bangladesh . Radioactive iodine therapy . Bangladesh atomic energy commission .

show abstract

Management of Patients with Differentiated Thyroid Carcinoma- SNMB Guidelines

Abstract: not availableBangladesh J. Nuclear Med. 18(1): 73-84, January 2015

Cited by 5 publications

References 0 publications

Follicular Thyroid Carcinoma Metastasis to the Skull and Brain: Case Series with Literature Review

Follicular Thyroid Carcinoma Metastasis to the Skull and Brain: Case Series with Literature Review

The incidence of postoperative re-stratification for recurrence in well-differentiated thyroid cancer—a retrospective cohort study

Theranostics in Bangladesh: Current Status, Challenges, and Future Perspective

Contact Info

Product

Resources

About